Vivani Medical (NASDAQ:VANI) Director Gregg Williams Purchases 29,929 Shares of Company Stock

Vivani Medical, Inc. (NASDAQ:VANI – Get Free Report) Director Gregg Williams bought 29,929 shares of Vivani Medical stock in a transaction that occurred on Tuesday, November 17th. The stock was purchased at an average cost of $1.05 per share, for a total transaction of $31,425.45. Following the purchase, the director owned 36,992,865 shares of the company’s stock, valued at $38,842,508.25. The trade was a 0.08% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Gregg Williams also recently made the following trade(s):

  • On Monday, November 16th, Gregg Williams acquired 2,100 shares of Vivani Medical stock. The stock was purchased at an average price of $1.01 per share, with a total value of $2,121.00.
  • On Friday, November 13th, Gregg Williams acquired 48,100 shares of Vivani Medical stock. The stock was purchased at an average price of $0.99 per share, with a total value of $47,619.00.

Vivani Medical Stock Performance

Shares of Vivani Medical stock opened at $1.05 on Thursday. The firm has a market capitalization of $94.71 million, a PE ratio of -3.28 and a beta of 2.51. The business’s 50-day moving average price is $1.16 and its 200-day moving average price is $1.23. Vivani Medical, Inc. has a 12 month low of $0.80 and a 12 month high of $1.66.

Vivani Medical (NASDAQ:VANI – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.01.

Analysts Set New Price Targets

Several research firms have commented on VANI. Wall Street Zen downgraded shares of Vivani Medical from a “hold” rating to a “sell” rating in a research note on Sunday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, October 2nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $3.75.

Get Our Latest Analysis on VANI

Vivani Medical Company Profile

(Get Free Report)

Vivani Medical is a clinical-stage medical technology company developing miniature, implantable devices designed to deliver medicines over extended periods. Its NanoPortal platform is intended to provide sustained drug delivery from a small implant placed under the skin, with the goal of reducing the need for frequent dosing. The company is advancing implant programs based on GLP-1 medicines for chronic conditions, including obesity and type 2 diabetes. These programs remain in development, and their availability and use depend on clinical and regulatory progress.

Featured Articles

Insider Buying and Selling by Quarter for Vivani Medical (NASDAQ:VANI)

Receive News & Ratings for Vivani Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivani Medical and related companies with MarketBeat.com's FREE daily email newsletter.